B Cell Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 17329
Special Issue Editor
Interests: B-cell lymphoma and leukemia; addiction to the B cell proliferation and survival program; targeting of non-oncogenic addictions; Goldilocks therapy of B-cell neoplasia
Special Issue Information
Dear Colleagues,
The B-cell lymphomas are the clonal malignancies derived from mature B cells at different stages of differentiation. Although some of the B-cell lymphoma subtypes are sensitive to conventional chemotherapy and are among the most curable tumors, most of them represent a therapeutic challenge. Importantly, B-cell lymphoma survivors still suffer from acute and delayed treatment complications of aggressive chemotherapy. The introduction of the therapeutic antibodies targeting B-cell markers, followed by the appearance of immune checkpoint inhibitors, and finally CAR-T cell immunotherapy, have further improved treatment results. Unfortunately, these new modalities are not able to cure all patients, and are not free of serious side effects.
Fortunately, growing knowledge on molecular mechanisms that are instrumental in oncogenic programs of B-cell lymphoma might open new opportunities for the therapy of B cell lymphoma. B-cell lymphomas, except for classical Hodgkin lymphoma, maintain the phenotype as well as the proliferation and survival program of their normal counterparts. In the process of maturation, B cells pass through sequential differentiation stages which rely on distinct, sometimes mutually exclusive, survival programs. The specific oncogenic program of B-cell lymphoma entities arises from the corresponding physiological program by the oncogenic activation of the physiological differentiation-stage-specific pro-survival pathways and by blocking the transition to the next differentiation stage. The identification of the role of particular pathways in specific sub-types of B-cell lymphoma has permitted the rational implementation of specific inhibitors, many of which have reached or already passed clinical trials.
These include inhibitors of proliferation and survival signaling such as LYN and SYK kinases, as well as PY3K, PI3K, AKT, and mTOR inhibitors; inhibitors of anti-apoptotic proteins BCL2 and BCL2L1; drugs targeting neoplasia-related proteotoxic stress like proteasome inhibitors; and epigenetic modifiers targeting tumor-specific transcriptional programs, including demethylating agents, HDAC, and BRD inhibitors.
This Special Issue is dedicated to broad molecular aspects of B-cell lymphoma pathogenesis and treatment with a focus on the distinctive features of the oncogenic programs of B cell lymphoma subtypes including regulation of transcription, translation, cellular metabolism. We believe that discovering new lineage-specific vulnerabilities and synthetic lethalities will help improve the therapy of B-cell lymphoma.
Dr. Alexey Ushmorov
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncogenic program of B cell lymphoma
- targeted therapy
- epigenetic therapy
- oncogenic dependency
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
